Skip to main content

Advertisement

SpringerLink
Log in

Crohn’s disease diagnosis, treatment approach, and management paradigm: what the radiologist needs to know

  • Invited article
  • Published:
Abdominal Radiology Aims and scope Submit manuscript

Abstract

Crohn’s disease is one of the major subtypes of idiopathic inflammatory bowel disease and is characterized by chronic transmural intestinal inflammation of the gastrointestinal tract anywhere from mouth to the anus, with a predilection for the small bowel. Cross-sectional imaging with computed tomography and magnetic resonance enterography plays a key role in confirming diagnosis, identifying and managing complications, assessing disease severity, and identifying response to medical therapy. This review will focus on the role of radiologists in the diagnosis and assessment of Crohn’s disease. Additionally, a review of current medical therapy approaches, available medications, and side effects will be discussed. The review will also highlight key complications of medical therapy and associated diseases that should be evaluated by the radiologist with cross-sectional imaging.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Courtesy Dr. Seong Ho Park, Asan Medical Center

Fig. 10
Fig. 11
Fig. 12

Similar content being viewed by others

References

  1. Baumgart DC, Sandborn WJ (2012) Crohn’s disease. Lancet 380(9853):1590–1605. doi:10.1016/s0140-6736(12)60026-9

    Article  PubMed  Google Scholar 

  2. Shivashankar R, Tremaine W, Harmsen S, Zinsmeister A, Loftus E (2014) Updated incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota (1970–2010). Am J Gastroenterol 109:499

    Google Scholar 

  3. Thia KT, Sandborn WJ, Harmsen WS, Zinsmeister AR, Loftus EV (2010) Risk factors associated with progression to intestinal complications of Crohn’s disease in a population-based cohort. Gastroenterology 139(4):1147–1155

    Article  PubMed  PubMed Central  Google Scholar 

  4. Peyrin-Biroulet L, Reinisch W, Colombel JF, et al. (2014) Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn’s disease in the SONIC trial. Gut 63(1):88–95. doi:10.1136/gutjnl-2013-304984

    Article  PubMed  Google Scholar 

  5. Silverberg MS, Satsangi J, Ahmad T, et al. (2005) Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 19(Suppl A):5A–36A

    Article  PubMed  Google Scholar 

  6. Lennard-Jones JE, Shivananda S (1997) Clinical uniformity of inflammatory bowel disease a presentation and during the first year of disease in the north and south of Europe. EC-IBD Study Group. Eur J Gastroenterol Hepatol 9(4):353–359

    Article  CAS  PubMed  Google Scholar 

  7. Fletcher JG, Fidler JL, Bruining DH, Huprich JE (2011) New concepts in intestinal imaging for inflammatory bowel diseases. Gastroenterology 140(6):1795–1806. doi:10.1053/j.gastro.2011.02.013

    Article  PubMed  Google Scholar 

  8. Deepak P, Fletcher JG, Fidler JL, et al. (2016) Radiological response is associated with better long-term outcomes and is a potential treatment target in patients with small bowel Crohn’s disease. Am J Gastroenterol 111(7):997–1006. doi:10.1038/ajg.2016.177

    Article  PubMed  Google Scholar 

  9. Deepak P, Fletcher JG, Fidler JL, Bruining DH (2016) Computed tomography and magnetic resonance enterography in Crohn’s disease: assessment of radiologic criteria and endpoints for clinical practice and trials. Inflamm Bowel Dis 22(9):2280–2288. doi:10.1097/mib.0000000000000845

    Article  PubMed  Google Scholar 

  10. Siddiki HA, Fidler JL, Fletcher JG, et al. (2009) Prospective comparison of state-of-the-art MR enterography and CT enterography in small-bowel Crohn’s disease. AJR Am J Roentgenol 193(1):113–121. doi:10.2214/ajr.08.2027

    Article  PubMed  Google Scholar 

  11. Seo N, Park SH, Kim KJ, et al. (2016) MR enterography for the evaluation of small-bowel inflammation in Crohn disease by using diffusion-weighted imaging without intravenous contrast material: a prospective noninferiority study. Radiology 278(3):762–772. doi:10.1148/radiol.2015150809

    Article  PubMed  Google Scholar 

  12. Bruining DH, Siddiki HA, Fletcher JG, et al. (2008) Prevalence of penetrating disease and extraintestinal manifestations of Crohn’s disease detected with CT enterography. Inflamm Bowel Dis 14(12):1701–1706. doi:10.1002/ibd.20529

    Article  PubMed  Google Scholar 

  13. Rimola J, Planell N, Rodriguez S, et al. (2015) Characterization of inflammation and fibrosis in Crohn’s disease lesions by magnetic resonance imaging. Am J Gastroenterol 110(3):432–440. doi:10.1038/ajg.2014.424

    Article  PubMed  Google Scholar 

  14. Bruining DH, Siddiki HA, Fletcher JG, et al. (2012) Benefit of computed tomography enterography in Crohn’s disease: effects on patient management and physician level of confidence. Inflamm Bowel Dis 18(2):219–225. doi:10.1002/ibd.21683

    Article  PubMed  Google Scholar 

  15. Deepak P, Bruining DH (2015) Update on the medical management of Crohn’s disease. Curr Gastroenterol Rep 17(11):41. doi:10.1007/s11894-015-0465-x

    Article  PubMed  Google Scholar 

  16. Sands BE (2004) From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology 126(6):1518–1532

    Article  PubMed  Google Scholar 

  17. Van Assche G, Dignass A, Panes J, et al. (2010) The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. J Crohns Colitis 4(1):7–27. doi:10.1016/j.crohns.2009.12.003

    Article  PubMed  Google Scholar 

  18. Jones J, Loftus EV Jr, Panaccione R, et al. (2008) Relationships between disease activity and serum and fecal biomarkers in patients with Crohn’s disease. Clin Gastroenterol Hepatol 6(11):1218–1224. doi:10.1016/j.cgh.2008.06.010

    Article  PubMed  Google Scholar 

  19. Iskandar HN, Ciorba MA (2012) Biomarkers in inflammatory bowel disease: current practices and recent advances. Transl Res 159(4):313–325. doi:10.1016/j.trsl.2012.01.001

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. De Cruz P, Kamm MA, Hamilton AL, et al. (2015) Crohn’s disease management after intestinal resection: a randomised trial. Lancet 385(9976):1406–1417. doi:10.1016/s0140-6736(14)61908-5

    Article  PubMed  Google Scholar 

  21. Menees SB, Powell C, Kurlander J, Goel A, Chey WD (2015) A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol 110(3):444–454. doi:10.1038/ajg.2015.6

    Article  CAS  PubMed  Google Scholar 

  22. Mylonaki M, Langmead L, Pantes A, Johnson F, Rampton DS (2004) Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. Eur J Gastroenterol Hepatol 16(8):775–778

    Article  PubMed  Google Scholar 

  23. Shergill AK, Lightdale JR, Bruining DH, et al. (2015) The role of endoscopy in inflammatory bowel disease. Gastrointest Endosc 81(5):1101-21.e1–1101-21.e13. doi:10.1016/j.gie.2014.10.030

  24. Nahon S, Bouhnik Y, Lavergne-Slove A, et al. (2002) Colonoscopy accurately predicts the anatomical severity of colonic Crohn’s disease attacks: correlation with findings from colectomy specimens. Am J Gastroenterol 97(12):3102–3107. doi:10.1111/j.1572-0241.2002.07106.x

    Article  PubMed  Google Scholar 

  25. Rutgeerts P, Onette E, Vantrappen G, et al. (1980) Crohn’s disease of the stomach and duodenum: a clinical study with emphasis on the value of endoscopy and endoscopic biopsies. Endoscopy 12(6):288–294. doi:10.1055/s-2007-1021762

    Article  CAS  PubMed  Google Scholar 

  26. Annunziata ML, Caviglia R, Papparella LG, Cicala M (2012) Upper gastrointestinal involvement of Crohn’s disease: a prospective study on the role of upper endoscopy in the diagnostic work-up. Dig Dis Sci 57(6):1618–1623. doi:10.1007/s10620-012-2072-0

    Article  PubMed  Google Scholar 

  27. Peyrin-Biroulet L, Sandborn W, Sands BE, et al. (2015) Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol 110(9):1324–1338. doi:10.1038/ajg.2015.233

    Article  CAS  PubMed  Google Scholar 

  28. Mary JY, Modigliani R (1989) Development and validation of an endoscopic index of the severity for Crohn’s disease: a prospective multicentre study. Groupe d’Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 30(7):983–989

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Daperno M, D’Haens G, Van Assche G, et al. (2004) Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc 60(4):505–512

    Article  PubMed  Google Scholar 

  30. Vuitton L, Marteau P, Sandborn WJ, et al. (2016) IOIBD technical review on endoscopic indices for Crohn’s disease clinical trials. Gut 65(9):1447–1455. doi:10.1136/gutjnl-2015-309903

    Article  CAS  PubMed  Google Scholar 

  31. Rutgeerts P, Geboes K, Vantrappen G, et al. (1990) Predictability of the postoperative course of Crohn’s disease. Gastroenterology 99(4):956–963

    Article  CAS  PubMed  Google Scholar 

  32. Koilakou S, Sailer J, Peloschek P, et al. (2010) Endoscopy and MR enteroclysis: equivalent tools in predicting clinical recurrence in patients with Crohn’s disease after ileocolic resection. Inflamm Bowel Dis 16(2):198–203. doi:10.1002/ibd.21003

    Article  PubMed  Google Scholar 

  33. Jensen MD, Nathan T, Rafaelsen SR, Kjeldsen J (2011) Diagnostic accuracy of capsule endoscopy for small bowel Crohn’s disease is superior to that of MR enterography or CT enterography. Clin Gastroenterol Hepatol 9(2):124–129. doi:10.1016/j.cgh.2010.10.019

    Article  PubMed  Google Scholar 

  34. Triester SL, Leighton JA, Leontiadis GI, et al. (2006) A meta-analysis of the yield of capsule endoscopy compared to other diagnostic modalities in patients with non-stricturing small bowel Crohn’s disease. Am J Gastroenterol 101(5):954–964. doi:10.1111/j.1572-0241.2006.00506.x

    Article  PubMed  Google Scholar 

  35. Doherty GA, Moss AC, Cheifetz AS (2011) Capsule endoscopy for small-bowel evaluation in Crohn’s disease. Gastrointest Endosc 74(1):167–175. doi:10.1016/j.gie.2011.01.067

    Article  PubMed  Google Scholar 

  36. Takenaka K, Ohtsuka K, Kitazume Y, et al. (2014) Comparison of magnetic resonance and balloon enteroscopic examination of the small intestine in patients with Crohn’s disease. Gastroenterology 147(2):334–342.e3. doi:10.1053/j.gastro.2014.04.008

    Article  PubMed  Google Scholar 

  37. Baker ME, Walter J, Obuchowski NA, et al. (2009) Mural attenuation in normal small bowel and active inflammatory Crohn’s disease on CT enterography: location, absolute attenuation, relative attenuation, and the effect of wall thickness. AJR Am J Roentgenol 192(2):417–423. doi:10.2214/ajr.08.1267

    Article  PubMed  Google Scholar 

  38. Siddiki H, Fletcher JG, Hara AK, et al. (2011) Validation of a lower radiation computed tomography enterography imaging protocol to detect Crohn’s disease in the small bowel. Inflamm Bowel Dis 17(3):778–786. doi:10.1002/ibd.21364

    Article  PubMed  Google Scholar 

  39. Macari M, Balthazar EJ (2001) CT of bowel wall thickening: significance and pitfalls of interpretation. AJR Am J Roentgenol 176(5):1105–1116. doi:10.2214/ajr.176.5.1761105

    Article  CAS  PubMed  Google Scholar 

  40. Plumb AA, Pendse DA, McCartney S, et al. (2014) Lymphoid nodular hyperplasia of the terminal ileum can mimic active crohn disease on MR enterography. AJR Am J Roentgenol 203(4):W400–407. doi:10.2214/ajr.13.12055

    Article  PubMed  Google Scholar 

  41. Meyers MA, McGuire PV (1995) Spiral CT demonstration of hypervascularity in Crohn disease: “vascular jejunization of the ileum” or the “comb sign”. Abdom Imaging 20(4):327–332

    Article  CAS  PubMed  Google Scholar 

  42. Rimola J, Ordas I, Rodriguez S, et al. (2011) Magnetic resonance imaging for evaluation of Crohn’s disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis 17(8):1759–1768. doi:10.1002/ibd.21551

    Article  PubMed  Google Scholar 

  43. Tielbeek JA, Makanyanga JC, Bipat S, et al. (2013) Grading Crohn disease activity with MRI: interobserver variability of MRI features, MRI scoring of severity, and correlation with Crohn disease endoscopic index of severity. AJR Am J Roentgenol 201(6):1220–1228. doi:10.2214/ajr.12.10341

    Article  PubMed  Google Scholar 

  44. Makanyanga J, Punwani S, Taylor SA (2012) Assessment of wall inflammation and fibrosis in Crohn’s disease: value of T1-weighted gadolinium-enhanced MR imaging. Abdom Imaging 37(6):933–943. doi:10.1007/s00261-011-9821-y

    Article  PubMed  Google Scholar 

  45. Kim KJ, Lee Y, Park SH, et al. (2015) Diffusion-weighted MR enterography for evaluating Crohn’s disease: how does it add diagnostically to conventional MR enterography? Inflamm Bowel Dis 21(1):101–109. doi:10.1097/mib.0000000000000222

    Article  CAS  PubMed  Google Scholar 

  46. Higgins PD, Fletcher JG (2015) Characterization of inflammation and fibrosis in Crohn’s disease lesions by magnetic resonance imaging. Am J Gastroenterol 110(3):441–443. doi:10.1038/ajg.2015.26

    Article  CAS  PubMed  Google Scholar 

  47. Barkmeier DT, Dillman JR, Al-Hawary M, et al. (2016) MR enterography-histology comparison in resected pediatric small bowel Crohn disease strictures: can imaging predict fibrosis? Pediatr Radiol 46(4):498–507. doi:10.1007/s00247-015-3506-6

    Article  PubMed  Google Scholar 

  48. Weber NK, Fletcher JG, Fidler JL, et al. (2015) Clinical characteristics and imaging features of small bowel adenocarcinomas in Crohn’s disease. Abdom Imaging 40(5):1060–1067. doi:10.1007/s00261-014-0144-7

    Article  PubMed  Google Scholar 

  49. Booya F, Akram S, Fletcher JG, et al. (2009) CT enterography and fistulizing Crohn’s disease: clinical benefit and radiographic findings. Abdom Imaging 34(4):467–475. doi:10.1007/s00261-008-9419-1

    Article  PubMed  Google Scholar 

  50. Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. (2002) The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology 122(4):875–880

    Article  PubMed  Google Scholar 

  51. Gecse KB, Bemelman W, Kamm MA, et al. (2014) A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn’s disease. Gut 63(9):1381–1392. doi:10.1136/gutjnl-2013-306709

    Article  PubMed  Google Scholar 

  52. Siddiqui MR, Ashrafian H, Tozer P, et al. (2012) A diagnostic accuracy meta-analysis of endoanal ultrasound and MRI for perianal fistula assessment. Dis Colon Rectum 55(5):576–585. doi:10.1097/DCR.0b013e318249d26c

    Article  PubMed  Google Scholar 

  53. Schwartz DA, Wiersema MJ, Dudiak KM, et al. (2001) A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn’s perianal fistulas. Gastroenterology 121(5):1064–1072

    Article  CAS  PubMed  Google Scholar 

  54. Ordas I, Feagan BG, Sandborn WJ (2011) Early use of immunosuppressives or TNF antagonists for the treatment of Crohn’s disease: time for a change. Gut 60(12):1754–1763. doi:10.1136/gutjnl-2011-300934

    Article  CAS  PubMed  Google Scholar 

  55. Sandborn WJ (2014) Crohn’s disease evaluation and treatment: clinical decision tool. Gastroenterology 147(3):702–705. doi:10.1053/j.gastro.2014.07.022

    Article  PubMed  Google Scholar 

  56. Terdiman JP, Gruss CB, Heidelbaugh JJ, Sultan S, Falck-Ytter YT (2013) American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-alpha biologic drugs for the induction and maintenance of remission in inflammatory Crohn’s disease. Gastroenterology 145(6):1459–1463. doi:10.1053/j.gastro.2013.10.047

    Article  PubMed  Google Scholar 

  57. Colombel JF, Sandborn WJ, Reinisch W, et al. (2010) Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 362(15):1383–1395. doi:10.1056/NEJMoa0904492

    Article  CAS  PubMed  Google Scholar 

  58. Dulai PS, Siegel CA, Colombel JF, Sandborn WJ, Peyrin-Biroulet L (2014) Systematic review: monotherapy with antitumour necrosis factor alpha agents versus combination therapy with an immunosuppressive for IBD. Gut 63(12):1843–1853. doi:10.1136/gutjnl-2014-307126

    Article  CAS  PubMed  Google Scholar 

  59. Targownik LE, Bernstein CN (2013) Infectious and malignant complications of TNF inhibitor therapy in IBD. Am J Gastroenterol 108(12):1835–1842; quiz 1843. doi:10.1038/ajg.2013.294

  60. Deepak P, Stobaugh DJ, Ehrenpreis ED (2013) Infectious complications of TNF-alpha inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System. J Gastrointest Liver Dis 22(3):269–276

    Google Scholar 

  61. Deepak P, Sifuentes H, Sherid M, et al. (2013) T-cell non-Hodgkin’s lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-alpha) inhibitors: results of the REFURBISH study. Am J Gastroenterol 108(1):99–105. doi:10.1038/ajg.2012.334

    Article  CAS  PubMed  Google Scholar 

  62. Kotlyar DS, Osterman MT, Diamond RH, et al. (2011) A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 9(1):36–41.e31. doi:10.1016/j.cgh.2010.09.016

  63. Long MD, Martin CF, Pipkin CA, et al. (2012) Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 143 (2):390-399 e391. doi:10.1053/j.gastro.2012.05.004

  64. Chande N, Tsoulis DJ, MacDonald JK (2013) Azathioprine or 6-mercaptopurine for induction of remission in Crohn’s disease. Cochrane Database Syst Rev (4):CD000545. doi:10.1002/14651858.CD000545.pub4

  65. Cosnes J, Bourrier A, Laharie D, et al. (2013) Early administration of azathioprine vs conventional management of Crohn’s Disease: a randomized controlled trial. Gastroenterology 145(4):758–765 e752; quiz e714–e755. doi:10.1053/j.gastro.2013.04.048

  66. Panes J, Lopez-Sanroman A, Bermejo F, et al. (2013) Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn’s disease. Gastroenterology 145(4):766–774 e761. doi:10.1053/j.gastro.2013.06.009

  67. Teml A, Schaeffeler E, Herrlinger KR, Klotz U, Schwab M (2007) Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet 46(3):187–208. doi:10.2165/00003088-200746030-00001

    Article  CAS  PubMed  Google Scholar 

  68. Kotlyar DS, Lewis JD, Beaugerie L, et al. (2015) Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol 13(5):847–858.e844; quiz e848–e850. doi:10.1016/j.cgh.2014.05.015

  69. Khan N, Abbas AM, Lichtenstein GR, et al. (2013) Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology 145(5):1007–1015 e1003. doi:10.1053/j.gastro.2013.07.035

  70. Gaies E, Jebabli N, Trabelsi S, et al. (2012) Methotrexate side effects: review article. J Drug Metab Toxicol 3(4):5

    Article  CAS  Google Scholar 

  71. Lichtenstein GR, Hanauer SB, Sandborn WJ (2009) Management of Crohn’s disease in adults. Am J Gastroenterol 104(2):465–483; quiz 464, 484. doi:10.1038/ajg.2008.168

  72. Buchman AL (2001) Side effects of corticosteroid therapy. J Clin Gastroenterol 33(4):289–294

    Article  CAS  PubMed  Google Scholar 

  73. Sandborn WJ, Feagan BG, Rutgeerts P, et al. (2013) Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 369(8):711–721. doi:10.1056/NEJMoa1215739

    Article  CAS  PubMed  Google Scholar 

  74. Sands BE, Feagan BG, Rutgeerts P, et al. (2014) Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 147(3):618–627 e613. doi:10.1053/j.gastro.2014.05.008

  75. Dulai PS, Singh S, Jiang X, et al. (2016) The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn’s disease: results From the US VICTORY Consortium. Am J Gastroenterol 111(8):1147–1155. doi:10.1038/ajg.2016.236

    Article  CAS  PubMed  Google Scholar 

  76. Deepak P, Loftus E Jr (2016) Ustekinumab in treatment of Crohn’s disease: design, development and potential place in therapy. Drug Des Dev Ther 10:3685–3698

    Article  Google Scholar 

  77. Sandborn W, Gasink C, Blank M, et al. (2016) O-001 a multicenter, double-blind, placebo-controlled Phase3 study of ustekinumab, a human IL-12/23P40 mAB, in moderate-service Crohn’s disease refractory to anti-TFNalpha: UNITI-1. Inflamm Bowel Dis 22(Suppl 1):S1. doi:10.1097/mib.0000000000000720

    Article  PubMed  Google Scholar 

  78. Feagan B, Gasink C, Lang Y, et al. (2015) OP054-LB4 A multicenter, double-blind, placebo-controlled Ph3 study of ustekinumab, a human monoclonal antibody to IL-12/23p40, in patients with moderately-severely active Crohn’s disease who are naïve or not refractory to anti-TNFa: UNITI-2 (abstract). United Eur Gastroenterol J 3(6):2

    Google Scholar 

  79. Sandborn W, Feagan BG, Gasink C, et al. (2016) 768 A Phase 3 randomized, multicenter, double-blind, placebo-controlled study of ustekinumab maintenance therapy in moderate-severe Crohn’s disease patients: results from IM-UNITI. Gastroenterology 150(4):S157–S158

    Google Scholar 

  80. FDA Approves STELARA® (ustekinumab) For treatment of adults with moderately to severely active Crohn’s disease. Janssen Biotech, Inc., Press Release, Sep 26, 2016, on the PR Newswire. http://www.prnewswire.com/news-releases/fda-approves-stelara-ustekinumab-for-treatment-of-adults-with-moderately-to-severely-active-crohns-disease-300333868.html. Accessed 7 Oct 2016

  81. Batista DD, Yadav S, Harmsen WS, et al. (2014) Su1420 ustekinumab treatment for Crohn’s disease in clinical practice: experience at a tertiary medical center. Gastroenterology 146(5):S-464–S-465

  82. Kopylov U, Afif W, Cohen A, et al. (2014) Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn’s disease—the McGill experience. J Crohns Colitis 8(11):1516–1522. doi:10.1016/j.crohns.2014.06.005

    Article  CAS  PubMed  Google Scholar 

  83. Khorrami S, Ginard D, Marin-Jimenez I, et al. (2016) Ustekinumab for the treatment of refractory Crohn’s disease: the Spanish experience in a large multicentre open-label cohort. Inflamm Bowel Dis 22(7):1662–1669. doi:10.1097/mib.0000000000000842

    Article  PubMed  Google Scholar 

  84. Wils P, Bouhnik Y, Michetti P, et al. (2016) Subcutaneous ustekinumab provides clinical benefit for two-thirds of patients with Crohn’s disease refractory to anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol 14(2):242–250 e241–242. doi:10.1016/j.cgh.2015.09.018

  85. Ford AC, Kane SV, Khan KJ, et al. (2011) Efficacy of 5-aminosalicylates in Crohn’s disease: systematic review and meta-analysis. Am J Gastroenterol 106(4):617–629. doi:10.1038/ajg.2011.71

    Article  CAS  PubMed  Google Scholar 

  86. Bouguen G, Levesque BG, Pola S, Evans E, Sandborn WJ (2014) Endoscopic assessment and treating to target increase the likelihood of mucosal healing in patients with Crohn’s disease. Clin Gastroenterol Hepatol 12(6):978–985. doi:10.1016/j.cgh.2013.11.005

    Article  PubMed  Google Scholar 

  87. Panaccione R, Colombel JF, Louis E, Peyrin-Biroulet L, Sandborn WJ (2013) Evolving definitions of remission in Crohn’s disease. Inflamm Bowel Dis 19(8):1645–1653. doi:10.1097/MIB.0b013e318283a4b3

    Article  PubMed  Google Scholar 

  88. Deepak P, Kolbe AB, Fidler JL, et al. (2016) Update on magnetic resonance imaging and ultrasound evaluation of Crohn’s disease. Gastroenterol Hepatol (N Y) 12(4):226–236

    Google Scholar 

  89. Panes J, Bouhnik Y, Reinisch W, et al. (2013) Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. J Crohns Colitis 7(7):556–585. doi:10.1016/j.crohns.2013.02.020

    Article  CAS  PubMed  Google Scholar 

  90. Van Assche G, Vanbeckevoort D, Bielen D, et al. (2003) Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn’s disease. Am J Gastroenterol 98(2):332–339. doi:10.1111/j.1572-0241.2003.07241.x

    Article  PubMed  Google Scholar 

  91. Horsthuis K, Lavini C, Bipat S, Stokkers PC, Stoker J (2009) Perianal Crohn disease: evaluation of dynamic contrast-enhanced MR imaging as an indicator of disease activity. Radiology 251(2):380–387. doi:10.1148/radiol.2512072128

    Article  PubMed  Google Scholar 

  92. Nikias G, Eisner T, Katz S, et al. (1995) Crohn’s disease and colorectal carcinoma: rectal cancer complicating longstanding active perianal disease. Am J Gastroenterol 90(2):216–219

    CAS  PubMed  Google Scholar 

  93. Ky A, Sohn N, Weinstein MA, Korelitz BI (1998) Carcinoma arising in anorectal fistulas of Crohn’s disease. Dis Colon Rectum 41(8):992–996

    Article  CAS  PubMed  Google Scholar 

  94. Iesalnieks I, Gaertner WB, Glass H, et al. (2010) Fistula-associated anal adenocarcinoma in Crohn’s disease. Inflamm Bowel Dis 16(10):1643–1648. doi:10.1002/ibd.21228

    Article  PubMed  Google Scholar 

  95. Baars JE, Kuipers EJ, Dijkstra G, et al. (2011) Malignant transformation of perianal and enterocutaneous fistulas is rare: results of 17 years of follow-up from The Netherlands. Scand J Gastroenterol 46(3):319–325. doi:10.3109/00365521.2010.536251

    Article  PubMed  Google Scholar 

  96. Lee HS, Park SH, Yang SK, et al. (2015) The risk of colorectal cancer in inflammatory bowel disease: a hospital-based cohort study from Korea. Scand J Gastroenterol 50(2):188–196. doi:10.3109/00365521.2014.989538

    Article  CAS  PubMed  Google Scholar 

  97. Penn I (1993) The effect of immunosuppression on pre-existing cancers. Transplantation 55(4):742–747

    Article  CAS  PubMed  Google Scholar 

  98. Beaugerie L (2014) Management of inflammatory bowel disease patients with a cancer history. Curr Drug Targets 15(11):1042–1048

    Article  CAS  PubMed  Google Scholar 

  99. Shelton E, Laharie D, Scott FI, et al. (2016) Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology 151(1):97–109.e104. doi:10.1053/j.gastro.2016.03.037

  100. Annese V, Beaugerie L, Egan L, et al. (2015) European evidence-based consensus: inflammatory bowel disease and malignancies. J Crohns Colitis 9(11):945–965. doi:10.1093/ecco-jcc/jjv141

    Article  PubMed  Google Scholar 

  101. Papa A, Papa V, Marzo M, et al. (2015) Prevention and treatment of venous thromboembolism in patients with IBD: a trail still climbing. Inflamm Bowel Dis 21(5):1204–1213. doi:10.1097/mib.0000000000000310

    Article  PubMed  Google Scholar 

  102. Purnak T, Yuksel O (2015) Overview of venous thrombosis in inflammatory bowel disease. Inflamm Bowel Dis 21(5):1195–1203. doi:10.1097/mib.0000000000000274

    Article  PubMed  Google Scholar 

  103. Yuhara H, Steinmaus C, Corley D, et al. (2013) Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease. Aliment Pharmacol Ther 37(10):953–962. doi:10.1111/apt.12294

    Article  CAS  PubMed  Google Scholar 

  104. Nguyen GC, Bernstein CN, Bitton A, et al. (2014) Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology 146(3):835–848.e836. doi:10.1053/j.gastro.2014.01.042

  105. Fumery M, Xiaocang C, Dauchet L, et al. (2014) Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: a meta-analysis of observational studies. J Crohns Colitis 8(6):469–479. doi:10.1016/j.crohns.2013.09.021

    Article  PubMed  Google Scholar 

  106. Harbord M, Annese V, Vavricka SR, et al. (2016) The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis 10(3):239–254. doi:10.1093/ecco-jcc/jjv213

    Article  PubMed  Google Scholar 

  107. Violi NV, Schoepfer AM, Fournier N, et al. (2014) Prevalence and clinical importance of mesenteric venous thrombosis in the Swiss Inflammatory Bowel Disease Cohort. AJR Am J Roentgenol 203(1):62–69. doi:10.2214/ajr.13.12447

    Article  PubMed  Google Scholar 

  108. Jess T, Gamborg M, Matzen P, Munkholm P, Sorensen TI (2005) Increased risk of intestinal cancer in Crohn’s disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol 100(12):2724–2729. doi:10.1111/j.1572-0241.2005.00287.x

    Article  PubMed  Google Scholar 

  109. Pellino G, Marcellinaro R, Candilio G, et al. (2016) The experience of a referral centre and literature overview of GIST and carcinoid tumours in inflammatory bowel diseases. Int J Surg 28(Suppl 1):S133–141. doi:10.1016/j.ijsu.2015.12.051

    Article  PubMed  Google Scholar 

  110. Pratico C, Rizzello F, Fornarini GS, et al. (2013) Four cases of carcinoid tumour in Crohn’s disease: coincidence or correlation? Int J Colorectal Dis 28(12):1743–1745. doi:10.1007/s00384-013-1732-7

    Article  PubMed  Google Scholar 

  111. Elsayed AM, Albahra M, Nzeako UC, Sobin LH (1996) Malignant melanomas in the small intestine: a study of 103 patients. Am J Gastroenterol 91(5):1001–1006

    CAS  PubMed  Google Scholar 

  112. Lens M, Bataille V, Krivokapic Z (2009) Melanoma of the small intestine. Lancet Oncol 10(5):516–521. doi:10.1016/s1470-2045(09)70036-1

    Article  PubMed  Google Scholar 

  113. Kovacs JA, Masur H (2000) Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N Engl J Med 342(19):1416–1429. doi:10.1056/nejm200005113421907

    Article  CAS  PubMed  Google Scholar 

  114. Park SH, Hwang SW, Kwak MS, et al. (2016) Long-term outcomes of infliximab treatment in 582 Korean patients with Crohn’s disease: a hospital-based cohort study. Dig Dis Sci 61(7):2060–2067. doi:10.1007/s10620-016-4105-6

    Article  CAS  PubMed  Google Scholar 

  115. Rahier JF, Magro F, Abreu C, et al. (2014) Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 8(6):443–468. doi:10.1016/j.crohns.2013.12.013

    Article  CAS  PubMed  Google Scholar 

  116. Karlsen TH, Schrumpf E, Boberg KM (2010) Update on primary sclerosing cholangitis. Dig Liver Dis 42(6):390–400. doi:10.1016/j.dld.2010.01.011

    Article  CAS  PubMed  Google Scholar 

  117. Rossi RE, Conte D, Massironi S (2016) Primary sclerosing cholangitis associated with inflammatory bowel disease: an update. Eur J Gastroenterol Hepatol 28(2):123–131. doi:10.1097/meg.0000000000000532

    CAS  PubMed  Google Scholar 

  118. Mowat C, Cole A, Windsor A, et al. (2011) Guidelines for the management of inflammatory bowel disease in adults. Gut 60(5):571–607. doi:10.1136/gut.2010.224154

    Article  PubMed  Google Scholar 

  119. Ramos LR, Sachar DB, DiMaio CJ, Colombel JF, Torres J (2016) Inflammatory bowel disease and pancreatitis: a review. J Crohns Colitis 10(1):95–104. doi:10.1093/ecco-jcc/jjv153

    Article  PubMed  Google Scholar 

  120. Park SH, Kim D, Ye BD, et al. (2013) The characteristics of ulcerative colitis associated with autoimmune pancreatitis. J Clin Gastroenterol 47(6):520–525. doi:10.1097/MCG.0b013e31827fd4a2

    Article  CAS  PubMed  Google Scholar 

  121. Shimosegawa T, Chari ST, Frulloni L, et al. (2011) International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas 40(3):352–358. doi:10.1097/MPA.0b013e3182142fd2

    Article  PubMed  Google Scholar 

  122. Maruyama M, Watanabe T, Kanai K, et al. (2013) International consensus diagnostic criteria for autoimmune pancreatitis and its Japanese Amendment have improved diagnostic ability over existing criteria. Gastroenterol Res Pract 2013:456965. doi:10.1155/2013/456965

    Article  PubMed  PubMed Central  Google Scholar 

  123. Ravi K, Chari ST, Vege SS, et al. (2009) Inflammatory bowel disease in the setting of autoimmune pancreatitis. Inflamm Bowel Dis 15(9):1326–1330. doi:10.1002/ibd.20898

    Article  PubMed  Google Scholar 

  124. Ueki T, Kawamoto K, Otsuka Y, et al. (2015) Prevalence and clinicopathological features of autoimmune pancreatitis in Japanese patients with inflammatory bowel disease. Pancreas 44(3):434–440. doi:10.1097/mpa.0000000000000261

    CAS  PubMed  Google Scholar 

  125. Klingenstein G, Levy RN, Kornbluth A, Shah AK, Present DH (2005) Inflammatory bowel disease related osteonecrosis: report of a large series with a review of the literature. Aliment Pharmacol Ther 21(3):243–249. doi:10.1111/j.1365-2036.2005.02231.x

    Article  CAS  PubMed  Google Scholar 

  126. Hauzeur JP, Malaise M, Gangji V (2009) Osteonecrosis in inflammatory bowel diseases: a review of the literature. Acta Gastroenterol Belg 72(3):327–334

    PubMed  Google Scholar 

  127. Nelson HD, Haney EM, Dana T, Bougatsos C, Chou R (2010) Screening for osteoporosis: an update for the U.S. Preventive Services Task Force. Ann Intern Med 153(2):99–111. doi:10.7326/0003-4819-153-2-201007200-00262

    Article  PubMed  Google Scholar 

  128. Weber NK, Fidler JL, Keaveny TM, et al. (2014) Validation of a CT-derived method for osteoporosis screening in IBD patients undergoing contrast-enhanced CT enterography. Am J Gastroenterol 109(3):401–408. doi:10.1038/ajg.2013.478

    Article  PubMed  PubMed Central  Google Scholar 

  129. Baker ME, Hara AK, Platt JF, Maglinte DD, Fletcher JG (2015) CT enterography for Crohn’s disease: optimal technique and imaging issues. Abdom Imaging 40(5):938–952. doi:10.1007/s00261-015-0357-4

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA

    Parakkal Deepak, Stephanie L. Hansel & David H. Bruining

  2. Department of Gastroenterology, Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

    Sang Hyoung Park

  3. Division of Abdominal Imaging, Mayo Clinic College of Medicine, 200 First Street, SW, Rochester, MN, 55905, USA

    Eric C. Ehman, Jeff L. Fidler & Joel G. Fletcher

Authors
  1. Parakkal Deepak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sang Hyoung Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eric C. Ehman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stephanie L. Hansel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jeff L. Fidler
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. David H. Bruining
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Joel G. Fletcher
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joel G. Fletcher.

Ethics declarations

Funding

No funding was received for this study.

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical approval

All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.

Informed consent

Statement of informed consent was not applicable since the manuscript does not contain any patient data.

Additional information

CME activity

This article has been selected as the CME activity for the current month. Please visit https://ce.mayo.edu/node/34281 and follow the instructions to complete this CME activity.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Deepak, P., Park, S.H., Ehman, E.C. et al. Crohn’s disease diagnosis, treatment approach, and management paradigm: what the radiologist needs to know. Abdom Radiol 42, 1068–1086 (2017). https://doi.org/10.1007/s00261-017-1068-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00261-017-1068-9

Keywords

Search

Navigation